Biotechnology companies have made stellar gains since the onset of the COVID-19 pandemic with an intense focus on developing vaccines and drugs. Governments worldwide made lofty investments to mitigate the public health crisis through mass vaccinations.
The rapid tech integration and substantial private and public investments have allowed major biotech companies to expand their product portfolio tremendously. Moreover, developments of new ways of treating and preventing major life-threatening diseases have helped the industry grow.
